Our Mission

To discover and develop novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs

News

Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

See All News

Events

Neuropore Therapies (NPT®) Presents at the 2018 Advances in Alzheimer's and Parkinson's Therapies ‐ an AAT ‐ AD/PD Focus Meeting in Torino, Italy  March 15th, 2018  The poster presentation entitled, "Beneficial effects of NPT520-34 in multiple models of neurodegenerative disorders", will be presented by Dr. Diana L. Price.

Click here for more information
See All Events

NPT® Publications

Neuropore publishes paper describing the discovery and characterization of a small molecule compound targeting α-synuclein as a potential Parkinson’s disease therapeutic October 5th, 2016

Report in Brain, describes findings supporting the hypothesis that NPT®100-18A reduces alpha-synuclein toxicity through a novel mechanism that involves displacing pathological alpha-synuclein from the membrane.

See All Publications

 

A team poised for success

About Our Team

Our Partners




Corporate

UCB Logo


Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore